Patent reform in the U.S. and EU, pricing pressures in numerous countries, increasing competition from emerging markets in Asia and Latin America and the global offensive against fake drugs. IPRM followed these issues and more to ensure that readers have the information they need to make smart business decisions in the U.S. and abroad. Here are some of the highlights of 2011 and a foreshadowing of challenges in the year ahead.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor